103,415 patents · 74,649 papers · 9,265 patents and 3,212 papers in the last 3 years.
Top assignees
- Genentech Inc (2,368 patents)
- Novartis AG (1,402 patents)
- Merck Sharp and Dohme LLC (1,272 patents)
Notable patents
- Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use (2003)
- Bis-anthracyclines with high activity against doxorubicin resistant tumors (1999)
- Derivatives of doxorubicine, their preparation and use (1981)
Notable papers
Top assignees
| Assignee | Patents |
|---|---|
| Genentech Inc | 2,368 |
| Novartis AG | 1,402 |
| Merck Sharp and Dohme LLC | 1,272 |
| AstraZeneca AB | 1,265 |
| Takeda Pharmaceutical Co Ltd | 1,105 |
| Bristol Myers Squibb Co | 1,018 |
| Abbott Cardiovascular Systems Inc | 896 |
| University of Texas System | 758 |
| University of California San Diego UCSD | 739 |
| F Hoffmann La Roche AG | 707 |
Top authors
| Author | Affiliation | Papers |
|---|---|---|
| Gabriel N. Hortobágyi | The University of Texas MD Anderson Cancer Center | 87 |
| Aman U. Buzdar | The University of Texas MD Anderson Cancer Center | 72 |
| Jun Wang | University of Science and Technology of China | 45 |
| Andreas Engert | University Hospital Cologne | 43 |
| Gianni Bonadonna | Fondazione IRCCS Istituto Nazionale dei Tumori | 38 |
| Hagop M. Kantarjian | The University of Texas MD Anderson Cancer Center | 33 |
| Peng Liu | Lanzhou University | 36 |
| Wei Zhang | Zhejiang University | 34 |
| Herbert M. Pinedo | Vrije Universiteit Amsterdam | 32 |
| Li Zhang | The University of Texas MD Anderson Cancer Center | 31 |
Top patents
| Title | Year | Assignee | Citations |
|---|---|---|---|
| Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use | 2003 | Immunogen Inc | 505 |
| Bis-anthracyclines with high activity against doxorubicin resistant tumors | 1999 | CHAIRES; JONATHAN B. | 98 |
| Derivatives of doxorubicine, their preparation and use | 1981 | INSTITUT INTERNATIONAL DE PATHOLOGIE CELLULAIRE ET MOLECULAIRE | 74 |
| Preparation of injectable doxorubicin/liposome suspension | 1990 | LIPOSOME TECHNOLOGY, INC. | 61 |
| Liposome/doxorubicin composition and method | 1990 | Hadassah Medical Organization | 52 |
Top papers
| Title | Year | Citations | Topic |
|---|---|---|---|
| Overexpression of a Transporter Gene in a Multidrug-Resistant Human Lung Cancer Cell Line | 1992 | 3052 | DNA and Nucleic Acid Chemistry |
| Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems | 2012 | 2432 | Nanoparticle-Based Drug Delivery |
| Elucidation of a Universal Size-Control Mechanism in Drosophila and Mammals | 2007 | 2429 | Wnt/β-catenin signaling in development and cancer |
| Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. | 1988 | 2365 | Cancer therapeutics and mechanisms |
| Protein carbonyl groups as biomarkers of oxidative stress | 2003 | 2336 | Pesticide Exposure and Toxicity |
Patent classifications
| Code | Area | Patents |
|---|---|---|
A61P | Therapeutic activity (drug indications) | 77,591 |
A61K | Medicinal preparations | 75,924 |
C07D | Heterocyclic compounds | 26,181 |
C07K | Peptides | 24,990 |
C12N | Microorganisms, enzymes | 11,597 |
G01N | Investigating / analysing materials | 9,975 |
Y02A | Climate change adaptation | 5,515 |
C12Q | Measuring/testing involving enzymes | 5,081 |
A61L | Sterilising / disinfecting materials | 4,106 |
C07C | Acyclic and carbocyclic compounds | 4,008 |
Research topics
| Topic | Papers |
|---|---|
| Lymphoma Diagnosis and Treatment | 103 |
| Nanoparticle-Based Drug Delivery | 94 |
| Chemotherapy-induced cardiotoxicity and mitigation | 72 |
| Drug Transport and Resistance Mechanisms | 55 |
| Cancer Treatment and Pharmacology | 38 |
| Sarcoma Diagnosis and Treatment | 34 |
| Bladder and Urothelial Cancer Treatments | 25 |
| Breast Cancer Treatment Studies | 25 |
| Cancer therapeutics and mechanisms | 18 |
| Hepatocellular Carcinoma Treatment and Prognosis | 18 |
Frequently asked questions
What is the molecular formula and weight of doxorubicin?
Doxorubicin has the molecular formula C27H29NO11 and a molecular weight of 543.525 g/mol. Its canonical IUPAC name is 7-(4-amino-5-hydroxy-6-methyloxan-2-yl)oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione.
Which organizations hold the most patents related to doxorubicin?
The leading patent holders in the doxorubicin space are Genentech Inc with 2,368 patents, Novartis AG with 1,402 patents, and Merck Sharp and Dohme LLC with 1,272 patents. Other major assignees include AstraZeneca AB, Takeda Pharmaceutical Co Ltd, and Bristol Myers Squibb Co.
What are the primary research topics associated with doxorubicin in the literature?
The major research topics include Lymphoma Diagnosis and Treatment, Nanoparticle-Based Drug Delivery, Chemotherapy-induced cardiotoxicity and mitigation, and Drug Transport and Resistance Mechanisms. Lymphoma Diagnosis and Treatment leads with 103 papers, followed by Nanoparticle-Based Drug Delivery with 94 papers.
What are the most highly cited papers on doxorubicin?
The highest-cited paper is 'Overexpression of a Transporter Gene in a Multidrug-Resistant Human Lung Cancer Cell Line' from 1992 with 3,052 citations. Another highly cited work is 'Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems' from 2012 with 2,432 citations.
What are the key patent CPC classifications for doxorubicin technology?
The most prevalent CPC subclasses associated with doxorubicin patents are A61P (Pharmaceutical preparations, 77,591 patents) and A61K (Preparations for medical purposes, 75,924 patents). Other significant classifications include C07D (organic chemistry, 26,181 patents) and C07K (peptide chemistry, 24,990 patents).